Creating faster and safer tests for viruses like COVID-19
Official title: Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses
Funded at Integral Molecular · NIH-11004045 · Data updated 2026-11-12
This study is working on a new virus test that helps quickly and safely check how well antibodies fight off viruses like COVID-19, making it easier for researchers to get faster results for vaccine trials and other important health studies.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Integral Molecular NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $288,515 |
| NIH project number | 1R43AI186556-01 |
| Project ID | NIH-11004045 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have been vaccinated against COVID-19 and are willing to provide serum samples for testing.
✕Less likely to help
Patients who are not vaccinated or have not been exposed to the COVID-19 virus may not benefit from this research.
What this research studies
This research focuses on developing a new type of virus called a Rapid Reporter Virus (RRV) that can quickly and safely assess how well antibodies neutralize viruses, including the COVID-19 virus. Traditional methods for measuring this, known as plaque reduction neutralization tests, are slow and can be subjective, making it challenging to analyze large numbers of samples. The RRV aims to streamline this process, allowing for faster results that can support vaccine trials and other clinical applications. By using optical reporters, the research seeks to enhance the efficiency and safety of virus testing.
Why it matters
Potential benefit: If successful, this research could lead to quicker and more reliable testing methods for neutralizing antibodies against viruses, improving vaccine development and public health responses.
How similar studies have gone: Other research has shown promise in using reporter viruses for similar applications, indicating that this approach could be effective.
Where this research is happening
-
Integral Molecular
Philadelphia, United States Active
Researchers
- Principal investigator: Doranz, Benjamin J — Integral Molecular
- Study coordinator: Doranz, Benjamin J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.